Analysis of rebleeding in cases of an upper gastrointestinal bleed in a single center series.


Journal

Revista espanola de enfermedades digestivas
ISSN: 1130-0108
Titre abrégé: Rev Esp Enferm Dig
Pays: Spain
ID NLM: 9007566

Informations de publication

Date de publication:
Mar 2019
Historique:
pubmed: 21 12 2018
medline: 10 3 2020
entrez: 21 12 2018
Statut: ppublish

Résumé

upper gastrointestinal bleeding (UGIB) is one of the main causes of hospital admission in gastroenterology departments and is associated with a significant morbidity and mortality. Rebleeding after initial endoscopic therapy occurs in 10-20% of cases and therefore, there is a need to define predictive factors for rebleeding. the aim of our study was to analyze risk factors and outcomes in a population of patients who suffered a rebleed. five hundred and seven patients with gastrointestinal bleeding were included. Clinical and biochemical data, as well as procedures and outcome six months after admission, were all collected. Documented clinical outcome included in-hospital and six-month delayed mortality, rebleeding and six-month delayed hemorrhagic and cardiovascular events. according to a logistic regression analysis, high creatinine levels were independent risk factors for rebleeding of non-variceal and variceal UGIB. In non-variceal UGIB, tachycardia was an independent risk factor, whereas albumin levels were an independent protective factor. Rebleeding was associated with in-hospital mortality (29.5% vs 5.5%; p < 0.0001). In contrast, rebleeding was not related to six-month delayed mortality or delayed cardiovascular and hemorrhagic events. tachycardia and high creatinine and albumin levels were independent factors associated with rebleeding, suggestive of a potential predictive role of these parameters. The incorporation of these variables into predictive scores may provide improved results for patients with UGIB. Further validation in prospective studies is required.

Sections du résumé

BACKGROUND BACKGROUND
upper gastrointestinal bleeding (UGIB) is one of the main causes of hospital admission in gastroenterology departments and is associated with a significant morbidity and mortality. Rebleeding after initial endoscopic therapy occurs in 10-20% of cases and therefore, there is a need to define predictive factors for rebleeding.
AIM OBJECTIVE
the aim of our study was to analyze risk factors and outcomes in a population of patients who suffered a rebleed.
METHODS METHODS
five hundred and seven patients with gastrointestinal bleeding were included. Clinical and biochemical data, as well as procedures and outcome six months after admission, were all collected. Documented clinical outcome included in-hospital and six-month delayed mortality, rebleeding and six-month delayed hemorrhagic and cardiovascular events.
RESULTS RESULTS
according to a logistic regression analysis, high creatinine levels were independent risk factors for rebleeding of non-variceal and variceal UGIB. In non-variceal UGIB, tachycardia was an independent risk factor, whereas albumin levels were an independent protective factor. Rebleeding was associated with in-hospital mortality (29.5% vs 5.5%; p < 0.0001). In contrast, rebleeding was not related to six-month delayed mortality or delayed cardiovascular and hemorrhagic events.
CONCLUSIONS CONCLUSIONS
tachycardia and high creatinine and albumin levels were independent factors associated with rebleeding, suggestive of a potential predictive role of these parameters. The incorporation of these variables into predictive scores may provide improved results for patients with UGIB. Further validation in prospective studies is required.

Identifiants

pubmed: 30569727
doi: 10.17235/reed.2018.5702/2018
doi:

Substances chimiques

Biomarkers 0
Serum Albumin 0
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-192

Auteurs

Rita Jiménez Rosales (R)

Gastroenterología, Hospital Universitario Virgen de Las Nieves, España.

Juan Gabriel Martínez-Cara (JG)

Hospital Universitario Virgen de Las Nieves.

Francisco Vadillo-Calles (F)

Hospital Universitario Virgen de Las Nieves, Hospital Universitario Virgen de Las Nieves.

Eva Julissa Ortega-Suazo (EJ)

Hospital Universitario Virgen de Las Nieves.

Patricia Abellán-Alfocea (P)

Hospital Universitario Virgen de Las Nieves.

Eduardo Redondo-Cerezo (E)

Aparato Digestivo, Hospital Virgen de las Nieves, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH